What Is Lymepak?
Lymepak (doxycycline hyclate tablets) is a tetracycline class antibiotic indicated for the treatment of early Lyme disease (as evidenced by erythema migrans) due to Borrelia burgdorferi in adults and pediatric patients 8 years of age and older weighing 45 kg and above.
What Are Side Effects of Lymepak?
Common side effects of Lymepak include:
- weight loss,
- sun sensitivity (photosensitivity),
- hives, and
- hemolytic anemia
Dosage for Lymepak
The dose of Lymepak for adults and pediatric patients 8 years of age and older weighing 45 kg and above is 100 mg every 12 hours, for 21 days.
What Drugs, Substances, or Supplements Interact with Lymepak?
Lymepak may interact with anticoagulants, penicillin, antacids (containing aluminum, calcium, or magnesium), bismuth subsalicylate and iron-containing preparations, oral contraceptives, isotretinoin, barbiturates, carbamazepine, and phenytoin. Tell your doctor all medications and supplements you use.
Lymepak During Pregnancy and Breastfeeding
Tell your doctor if you are pregnant or plan to become pregnant before using Lymepak. The use of Lymepak during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown) and defects in the tooth enamel. Lymepak passes into breast milk. Breastfeeding is not recommended while using Lymepak.
Our Lymepak (doxycycline hyclate tablets) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
The following clinically significant adverse reactions are described elsewhere in the labeling:
- Tooth Discoloration and Enamel Hypoplasia [see WARNINGS AND PRECAUTIONS]
- Inhibition of Bone Growth [see WARNINGS AND PRECAUTIONS]
- Clostridium Difficile Associated Diarrhea [see WARNINGS AND PRECAUTIONS]
- Photosensitivity [see WARNINGS AND PRECAUTIONS]
- Severe Skin Reactions [see WARNINGS AND PRECAUTIONS]
- Jarisch-Herxheimer reaction [see WARNINGS AND PRECAUTIONS]
- Intracranial Hypertension [see WARNINGS AND PRECAUTIONS]
The following adverse reactions have been observed during clinical trials or post-approval use of tetracycline-class drugs, including LYMEPAK. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Anorexia, nausea, vomiting, diarrhea, glossitis, dysphagia, enterocolitis, and inflammatory lesions (with monilial overgrowth) in the anogenital region, and pancreatitis. Hepatotoxicity has been reported. These reactions have been caused by both the oral and parenteral administration of tetracyclines. Superficial discoloration of the adult permanent dentition, reversible upon drug discontinuation and professional dental cleaning has been reported. Permanent tooth discoloration and enamel hypoplasia may occur with drugs of the tetracycline class when used during tooth development [see WARNINGS AND PRECAUTIONS]. Esophagitis and esophageal ulcerations have been reported in patients receiving capsule and tablet forms of drugs in the tetracycline-class. Most of these patients took medications immediately before going to bed [see DOSAGE AND ADMINISTRATION].
Toxic epidermal necrolysis, Stevens-Johnson syndrome, erytherma multiforme, maculopapular and erythematous rashes. Exfoliative dermatitis has been reported but is uncommon. Photosensitivity is discussed above [see WARNINGS AND PRECAUTIONS].
Rise in BUN has been reported and is apparently dose-related [see WARNINGS AND PRECAUTIONS].
Hypersensitivity reactions including urticaria, angioneurotic edema, anaphylaxis, anaphylactoid purpura, serum sickness, pericarditis, exacerbation of systemic lupus erythematosus and drug reaction with eosinophilia and systemic symptoms (DRESS). Jarisch-Herxheimer reaction has been reported in patients treated with doxycycline for early Lyme disease [see WARNINGS AND PRECAUTIONS].
Hemolytic anemia, thrombocytopenia, neutropenia, and eosinophilia have been reported.
Intracranial hypertension (IH, pseudotumor cerebri) in adults and bulging fontanels in infants has been associated with the use of tetracycline [see WARNINGS AND PRECAUTIONS].
Thyroid Gland Changes
When given over prolonged periods, tetracyclines have been reported to produce brown-black microscopic discoloration of thyroid glands. No abnormalities of thyroid function are known to occur.
Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.
Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines, including LYMEPAK in conjunction with penicillin.
Antacids And Iron Preparations
Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate, and iron-containing preparations. Absorption of tetracyclines is impaired by bismuth subsalicylate.
Concurrent use of tetracycline, including LYMEPAK, may render oral contraceptives less effective.
There have been reports of intracranial hypertension associated with the concomitant use of isotretinoin and doxycycline. Avoid the concomitant use of isotretinoin and LYMEPAK because isotretinoin is also known to cause pseudotumor cerebri (benign intracranial hypertension [see WARNINGS AND PRECAUTIONS].
Barbiturates And Anti-Epileptics
Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.
Drug/Laboratory Test Interactions
False elevations of urinary catecholamines may occur due to interference with the fluorescence test.
Read the entire FDA prescribing information for Lymepak (Doxycycline Hyclate Tablets)
© Lymepak Patient Information is supplied by Cerner Multum, Inc. and Lymepak Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.
Health Solutions From Our Sponsors